Tetraphase's antibiotic 'as good as Merck's' in Phase III
This article was originally published in Scrip
Executive Summary
Tetraphase Pharmaceuticals' share price soared on news that eravacycline, its novel antibiotic to treat complicated intra-abdominal infections, was as effective as Merck & Co's ertapenem in the Phase III IGNITE 1 study. Its shares closed more than 10% up at $33.19 on 17 December.